DEXTROPROPOXYPHENE except when included in Schedule 4.
DIFENOXIN except when included in Schedule 4.
DIHYDROCODEINE except when included in Schedule 3 or 4.
DIHYDROMORPHINE.
N, α ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder.
DIPHENOXYLATE except when included in Schedule 3 or 4.
DIPIPANONE.
DRONABINOL (delta‑9‑tetrahydrocannabinol) when prepared and packed for therapeutic use.
DROTEBANOL.
ESKETAMINE.
ETHYLAMFETAMINE.
ETHYLMORPHINE except when included in Schedule 2 or 4.
NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use.
NORCODEINE.
NORMETHADONE.
OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.
3,4,5‑TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy‑phenylethylamine except:
(a) methoxyphenamine; or
1‑(3,4,5‑TRIMETHOXYPHENYL)‑2‑AMINOBUTANE.
Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use
Note 1: See subsection 57(2) and section 63.
Note 2: Schedule 10 contains substances previously included in Appendix C.
ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.
ACORUS CALAMUS (calamus) for human therapeutic use.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:
(a) in liquid or semi‑solid food additive preparations, the pH of which is more than 11.5; or
(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
(c) in liquid or semi‑solid automatic dishwashing preparations, the pH of which is more than 12.5.
ALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in these schedules.
2‑AMINO‑5‑METHYLPHENOL in preparations for cosmetic use.
AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.
AMYGDALIN for therapeutic use.
ANCHUSA OFFICINALIS for therapeutic use.
o‑ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of o‑anisidine.
APRONAL for therapeutic use.
ARISTOLOCHIA spp. for therapeutic use.
ARISTOLOCHIC ACID(S) for human therapeutic use.
ASARUM spp. containing aristolochic acid(s) for human therapeutic use.
AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except “debitterised neem seed oil”.
BASIC ORANGE 31 (2‑[(4‑aminophenyl)azo]‑1,3‑dimethyl‑1H‑imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.
1,2‑BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).
1,3‑BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).
BITHIONOL for human therapeutic use.
BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.
BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.
BUCLOSAMIDE for therapeutic use.
BUNIODYL SODIUM for therapeutic use.
1,4‑BUTANEDIOL (excluding its derivatives) in non‑polymerised form in preparations for domestic use.
BUTYL BENZYL PHTHALATE for cosmetic use.
CACALIA spp. for therapeutic use.
CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.
CARDARINE.
CHRYSOIDINE BASE in preparations for use in hair dyes.
CINCHOPHEN and its derivatives for therapeutic use.
CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use except or when being used solely for experimental purposes in humans and where such use:
(a) is in accordance with:
(i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and
(ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Act; and
(iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Act; or
(b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.
COAL TAR for cosmetic use other than in therapeutic goods.
CONIUM MACULATUM (coniine) for therapeutic use.
COTARNINE for therapeutic use.
CROTALARIA spp. for therapeutic use.
CROTON TIGLIUM for therapeutic use.
CYNOGLOSSUM spp. for therapeutic use.
DIBUTYL PHTHALATE for cosmetic use.
DICOPHANE (DDT) for therapeutic use.
DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of diethylene glycol.
DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.
DIETHYLHEXYL PHTHALATE for cosmetic use.
DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of diethylphthalate.
5,6‑DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6‑dihydroxyindoline.
DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.
DIISOBUTYL PHTHALATE for cosmetic use.
1,3‑DIMETHYLAMYLAMINE (DMAA).
1,3‑DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules.
1,5‑DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these schedules.
DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.
1,4‑DIMETHYLPENTYLAMINE (DMPA).
DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of dimethylphthalate.
2,4‑DINITROPHENOL for human use.
DISPERSE YELLOW 3 for use in hair dyes.
DULCIN for therapeutic use.
ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of ethylene glycol.
EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.
FARFUGIUM JAPONICUM for therapeutic use.
FORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or
(b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:
GAMMA BUTYROLACTONE (excluding its derivatives) in non‑polymerised form in preparations for domestic and cosmetic use.
HELIOTROPIUM spp. for therapeutic use.
HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.
ISOPROPYL NITRITE.
JUNIPERUS SABINE [savin(e)] for therapeutic use.
KAMBO.
LEAD COMPOUNDS:
(a) in anti‑fouling paints except in preparations containing 0.1% or less of lead calculated on the non‑volatile content of the paint; or
(b) in paints (other than anti‑fouling paints), tinters, inks or ink additives except in preparations containing 0.009% or less of lead calculated on the non‑volatile content of the paint, tinter, ink or ink additive; or
(c) for human therapeutic use except in preparations containing 10 mg/kg or less of lead.
LIGULARIA DENTATA for therapeutic use.
MELIA AZEDARACH including its extracts and derivatives.
METHANOL in hand sanitiser preparations containing more than 5% methanol.
METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.
METHYL METHACRYLATE for cosmetic use except in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.
METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes:
(a) Acid Violet 49; or
(b) Ethyl Violet; or
(c) Basic Blue 7; or
(d) Basic Blue 26 (CI 44045).
NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use except when enclosed in a device which, in normal use, prevents removal or ingestion of its contents.
OXYPHENISATIN for therapeutic use.
PARAFORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or
(b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:
PETASITES spp. for therapeutic use.
PHENPROMETHAMINE.
PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows except when included in Schedule 6.
POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi‑solid food additive preparations, for domestic use, the pH of which is more than 11.5.
n‑PROPYL NITRITE.
PTERIDIUM spp. for therapeutic use.
PULMONARIA spp. for therapeutic use.
SAFROLE for internal therapeutic use except in preparations containing 0.1% or less of safrole.
SANGUINARIA CANADENSIS (bloodroot) in preparations for human use except in preparations containing 0.01% or less of SANGUINARINE.
SENECIO spp. for therapeutic use.
SILICONES for injection or implantation except when included in Schedule 4.
SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi‑solid food additive preparations, for domestic use, the pH of which is more than 11.5.
SYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in Schedule 5.
2,4‑TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.
TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows except when included in Schedule 6.
o‑TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of o‑toluidine.
1,1,1‑TRICHLOROETHANE in pressurised spray packs for therapeutic use.
TRICHODESMA AFRICANA for therapeutic use.
TRIPARANOL for therapeutic use.
TUSSILAGO FARFARA for therapeutic use.
Appendix A—General exemptions
Note: See paragraph 11(a).
1 Exempt preparations and products
The following table specifies preparations and products for the purposes of paragraph 11(a).
Exempt preparations and products
Item Column 1 Preparation or product
1 ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that are not agricultural chemical products or veterinary chemical products
2 BACTERIAL CULTURE MEDIA containing antibiotics
3 CERAMICS
4 CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4‑2003, Safety of toys, Part 4: Experimental sets for chemistry and related activities
5 COPPER COMPOUNDS in paints
6 DEXTRANS, GELATIN ‑ SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders
7 ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS
8 ELECTRONIC COMPONENTS
9 ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging
10 EXPLOSIVES
11 FOOD except:(a) food additives before incorporation into food; or(b) when used as a means of administering a poison for therapeutic use
12 FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non‑migratory component of glassy solid flakes or granules
13 GLASS (including CRYSTAL WARE)
14 GLAZED POTTERY
15 HUMAN BLOOD PRODUCTS including:(a) whole blood;(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and(c) the following plasma‑derived therapeutic proteins; and their equivalent recombinant alternatives:(i) albumin;(ii) anticoagulation complex;(iii) C1 esterase inhibitors;(iv) clotting factors;(v) fibrinogen;(vi) protein C;(vii) prothrombin complex concentrate (PCC);(viii) thrombin
16 IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001% or less of a poison included in Schedules 1 to 8
17 INTRAOCULAR VISCOELASTIC PRODUCTS
18 LUBRICANTS in preparations that provide a lubricating action between machinery parts, except soluble oils and solvent‑deposited lubricating agents
19 MATCHES
20 MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
21 MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, except the following:(a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;(b) medical devices which include anticoagulants;(c) artificial tears;(d) urinary catheters;(e) intra‑articular fluids
22 MOTOR, HEATING or FURNACE FUELS except the following:(a) when the contrary intention appears in any Schedule;(b) when containing methanol;(c) toy or hobby fuels; or(d) petrol or kerosene when packed in containers having a capacity of 20 L or less
23 NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION
24 PAPER except:(a) when prepared for pesticidal use; or(b) when containing a poison included in Schedule 8 or 9
25 PHOTOGRAPHIC PAPER or FILM
26 PIGMENTS when immobilised in a polymer
27 PORCELAIN
28 PRINTING INKS or INK ADDITIVES except:(a) when containing a pesticide; or(b) preparations containing more than 0.009% of lead calculated on the non‑volatile content of the ink or ink additive
29 RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use
30 RADIOISOTOPES for therapeutic use
31 SEEDS treated with seed protectants
32 SINGLE‑USE TUBES for the estimation of alcohol content of breath
33 TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting
34 TIMBER or WALLBOARD
35 TREATMENT LAYERS OF COATED METAL ARTICLES except articles intended for use in the collection of drinking water when not compliant with the health and safety requirements of the Australian Standard AS 4020:2018, Testing of products for use in contact with drinking water
36 VITREOUS ENAMELS
37 WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5
Appendix B—Substances considered not to require control by scheduling
Note: See paragraph 11(b).
1 Reasons for including substances in the table in clause 3
For the purposes of the table in clause 3, the letter specified in column 1 of an item of the following table represents the reason specified in column 2 of the item.
Reasons for including substances in the table in clause 3
Item Column 1 Letter Column 2 Reason
1 a Low Toxicity
2 b Use pattern restricts hazard
3 c Presentation/packaging restricts hazard
4 d Industrial use only
2 Areas of use in relation to substances included in the table in clause 3
For the purposes of the table in clause 3, the number specified in column 1 of an item of the following table represents the area, sub‑area or sub‑sub‑area of use specified in column 2, 3 or 4 (as applicable) of the item.
Areas of use in relation to substances included in the table in clause 3
Item Column 1 Number Column 2 Area Column 3 Sub‑area Column 4 Sub‑sub‑area
1 1 Agriculture
2 1.1 Herbicide
3 1.2 Insecticide
4 1.2.1 Insecticide for codling moth
5 1.2.2 Termiticide
6 1.3 Fungicide
7 1.3.1 On seed fungicide
8 1.4 Bird Repellent
9 1.5 Fertiliser
10 1.6 Plant Growth Regulator
11 1.7 Insect Pheromone
12 1.8 Mushroom Bactericide
13 1.9 Acaricide
14 1.10 Biological control agent
15 1.11 Adjuvant in agricultural products
16 2 Veterinary
17 2.1 For animal use
18 2.2 Treatment of mastitis in cows
19 2.3 Coccidiostat
20 2.4 Feed additive
21 2.5 Antiseptic
22 2.6 Scabicide
23 2.7 Anthelmintic
24 2.8 Vitamin/Mineral
25 2.9 Growth Promotant
26 2.10 Ectoparasiticide
27 3 Domestic
28 3.1 Aromatherapy
29 3.2 Food additive
30 3.3 Cosmetic
31 3.4 Human use
32 3.5 Miticide
33 4 Industrial
34 4.1 Water treatment
35 4.2 Biological control agent
36 5 Environmental
37 5.1 Mosquito control
38 6 Human therapeutic use
39 6.1 Diagnostic agent
40 6.2 Medical device
41 6.3 Antiseptic
42 6.4 Sunscreen
43 6.5 External use
44 6.6 Laxative
45 6.7 Antiseborrheic
46 6.8 Cytoprotective
47 6.9 Vitamin/Mineral
48 6.10 Eye Drops
49 7 General
50 7.1 Any use
51 7.2 Excipient
52 7.3 Synergist
53 7.4 Flux
54 7.5 Pesticide
55 7.6 Insect repellent
56 7.7 Solvent
57 7.8 Disinfectant
58 7.9 Preservative
59 7.10 Antioxidant
60 7.11 Resin activator/accelerant
61 7.12 Sweetener artificial
62 7.13 Food additive
3 Substances exempt in certain uses
For the purposes of paragraph 11(b), the following table specifies:
(a) substances; and
(b) areas, sub‑areas and sub‑sub‑areas of use in relation to those substances.
Note: Columns 3 and 4 of the table are included for information only.
Substances exempt in certain uses
Item Column 1 Substance Column 2 Area, sub‑area or sub‑sub‑area of use Column 3 Reason for inclusion Column 4 Date of inclusion
1 4‑[4‑(ACETYLOXY)PHENYL]‑2‑BUTANONE 1.7 b Feb 2005
2 AFIDOPYROPEN 1.2 b Jun 2018
3 ALCOHOL, DEHYDRATED 6 b Aug 2000
4 ALUM 7.1 a May 1997
5 ALUMINIUM AMMONIUM SULFATE 7.1 a May 1997
6 ALUMINIUM POTASSIUM SULFATE 7.1 a May 1997
7 ALUMINIUM SILICATE 7.1 a Nov 1974
8 ALUMINIUM tris (ETHYLPHOSPHONATE) 1 a Aug 1986
9 AMETOCTRADIN 1.3 a May 2012
10 AMMONIUM PHOSPHATE 7.1 a Nov 1974
11 AMMONIUM THIOSULPHATE 7.1 a Nov 1974
12 AMPROLIUM 2.3 a Jun 1969
13 AMYL ACETATE 7.1 a Nov 1974
14 α ‑AMYLASE derived from Aspergillus niger 2.4 a Feb 2005
15 AMYL CINNAMALDEHYDE 3.3 a, b Feb 2017
16 ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT 2.1 a Jun 2004
17 ASPARTIC ACID 6 a ‑
18 ASULAM 1 a May 1986
19 AUREOBASIDIUM PULLULANS (strains DSM14940 and DSM14941) 1.3 a Oct 2017
20 AZIMSULFURON 1.1 a Jun 2003
21 BACILLUS AMYLOLIQUEFACIENS 1.3 a Jun 2018
22 BACILLUS SPHAERICUS, STRAIN 2362 5.1 a Feb 2003
23 BACILLUS THURINGIENSIS 5.1 a May 1992
24 BACILLUS THURINGIENSIS (excluding endotoxin) 2.10 a Jun 2003
25 BACILLUS TOYOI 2.9 a Aug 1980
26 BACULOVIRUS CYDIA POMONELLA 1.2 a Jun 2006
27 BENFLURALIN 1.1 a ‑
28 BENSULFURON‑METHYL 1 a Aug 1987
29 BENTONITE 7.1 a Jun 2002
30 BENZYL BENZOATE 1.2 a Aug 1989
31 BETAINE HYDROCHLORIDE 7.1 a Nov 1974
32 BIFENAZATE 1.9 a Oct 2002
33 BISMUTH SUBNITRATE 2.1 b, c Nov 1999
34 BISTRIFLURON 1.2.2 a Feb 2014
35 BIURET 2.4 a Nov 1974
36 BIXLOZONE 1.1 a Feb 2020
37 BLAD (banda de Lupinus albus doce) 1.3 a Feb 2016
38 BOSCALID 1.3 a June 2003
39 BOVINE SOMATOTROPHIN 2 a May 1992
40 BROMACIL 1 a Aug 1987
41 BROMOPROPYLATE 1 a Nov 1994
42 BUPIRIMATE 1 a Nov 1990
43 BUTAFENACIL 1 a May 2000
44 BUTOXYPOLYPROPYLENE GLYCOL 7.7 a Nov 1974
45 n‑BUTYL BUTYRATE 7.1 a ‑
46 n‑BUTYL LACTATE 7.1 a ‑
47 CARBOXIN 1 a Aug 1987
48 CARFENTRAZONE‑ETHYL 1 a Aug 1998
49 CELLULASE derived from Aspergillus niger 2.4 a Feb 2005
50 CETYL ALCOHOL 7.1 a Nov 1974
51 CHAMOMILE OIL 3.1 a Feb 2000
52 CHINA CLAY 1.2 a Sep 2008
53 CHLORANTRANILIPROLE 1.2 a Sep 2008
54 CHLORFLUAZURON 1.2.2 a Oct 2005
55 CHLORFLURENOL 1.6 a Feb 1974
56 CHLORIDAZON 1 a May 1988
57 CHLOROXYLENOLS 7.8 a Feb 1975
58 CITRONELLA OIL 7.1 a Feb 2000
59 CLARY SAGE OIL 7.1 a Feb 2000
60 CLITORIA TERNATEA EXTRACT 1.2 a Feb 2016
61 CLOPIDOL 2.3 d Nov 1974
62 COBALT NAPHTHENATE 7.1 d ‑
63 CROSPOVIDONE 2 a Aug 1996
64 CULICINOMYCES CLAVOSPORUS 5.1 a Nov 1982
65 CYCLAMIC ACID 7.1 a Nov 1971
66 CYCLANILIPROLE 1.2 a Oct 2016
67 CYCLOBUTRIFLURAM 1.3, 1.3.1 a Oct 2022
68 CYCLOHEXANE 7.7 a Nov 1974
69 CYCLOHEXANOL ACETATE 7.7 a ‑
70 CYPRINID HERPESVIRUS‑3 1.10 a Oct 2018
71 CYROMAZINE 2 a Nov 1980
72 DICLAZURIL 2.3 a Nov 2001
73 DIETHYL CARBONATE 7.1 a ‑
74 DIFLUFENICAN 1 a Feb 1987
75 DIKEGULAC‑SODIUM 1.6 a Mar 1980
76 DIMETHYL ETHER 4 d Nov 1988
77 DIMETICONE 7.1 a ‑
78 DIPHENYLAMINE 1 a Feb 1988
79 DIPROPYLENE GLYCOL MONOMETHYL ETHER 4 a Nov 1987
80 DISODIUM MANGANESE EDTA 2.1 a Feb 2022
81 DIURON 1 a Nov 1987
82 DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) 7.1 a Feb 1970
83 2,2‑DPA 1 a Nov 1989
84 DROMETRIZOLE TRISILOXANE 6.4 a Oct 2003
85 DUDDINGTONIA FLAGRANS, STRAIN IAH 1297 2.7 a Feb 2018
86 EPSIPRANTEL 2 a Nov 1991
87 ETHAMETSULFURON‑METHYL 1.1 a Nov 2000
88 ETHOPABATE 2.3 d Jun 1969
89 ETHYL ACETATE 7.1 a Nov 1974
90 ETHYL ALCOHOL 7.1 a Nov 1974
91 ETHYLBUTYLACETYL AMINOPROPRIONATE 3.4 a Aug 2000
92 ETHYL BUTYRATE 7.1 a ‑
93 ETHYL LACTATE 7.1 a ‑
94 ETOFENPROX 1.2 a Jun 2018
95 ETOXAZOLE 1.2 a Oct 2003
96 EUBACTERIUM sp. strain DSM11798 2.4 a Sep 2013
97 FENFURAM 1.3.1 a May 1977
98 FENHEXAMID 1 a Feb 1999
99 FENOXYCARB 1 a Feb 1988
100 FLORPYRAUXIFEN‑BENZYL 1, 1.1 a Feb 2018
101 FLORYLPICOXAMID 1.3 a Feb 2021
102 FLUFENOXURON 1 a Feb 1997
103 FLUMETSULAM 1 a Feb 1992
104 FLUOMETURON 1 a Aug 1989
105 FLUOPICOLIDE 1.3 a Oct 2016
106 FLUOXAPIPROLIN 1.3 a Feb 2022
107 FLUTOLANIL 1.3 a Nov 2001
108 FLUROXYPYR 1 a, c May 1986
109 FORCHLORFENURON 1.6 a Feb 2005
110 FULLERS EARTH 7.1 a Nov 1974
111 FUNGAL PROTEASE derived from Aspergillus niger 2.4 a Feb 2005
112 GERANIUM OIL 7.1 a Feb 2000
113 GIBBERELLIC ACID 1.6 a Nov 1974
114 α‑GLUCANASE derived from Aspergillus niger 2.4 a Feb 2005
115 HALAUXIFEN METHYL 1, 1.1 a Oct 2014
116 HELIONAL 7 a Feb 2023
117 HEXAFLURON 1 a Nov 1988
118 HEXYL ACETATE 7.7 a ‑
119 HEXYL CINNAMALDEHYDE 3.3 a, b Feb 2017
120 HEXYTHIAZOX 1 a Feb 1988
121 HUMAN OSTEOGENIC PROTEIN‑1 (OP‑1) 6.2 b Aug 2001
122 HYDROPRENE 1 a Feb 1988
123 HYDROXYPROPYL CELLULOSE 7.1 a Nov 1982
124 ICODEXTRIN 6 b Nov 2000
125 INDOLE‑3‑ACETIC ACID 1.6 b Feb 1985
126 IPFLUFENOQUIN 1.3, 1.3.1 a Sep 2022
127 ISOPRENE ALCOHOL 7.1 a ‑
128 IPRODIONE 1 a Feb 1997
129 ISETHIONATE, as mixed ammonium and ethanolamine salts of 2‑hydroxyethanesulfonic acid 1.11 a, b Jun 2016
130 ISOFETAMID 1.3 a Feb 2018
131 ISOSTEARYL ALCOHOL ETHOXYLATE 5.1 a Nov 1999
132 KAOLIN 7.1 a Nov 1974
133 KINETIN 1.6 a Feb 2022
134 KRESOXIM‑METHYL 1 a Aug 1999
135 KUNZEA OIL 7.1 a Feb 2000
136 LAURIC ACID 7.1 a Oct 2005
137 LAURYL ALCOHOL (1‑DODECANOL) 7.1 a Nov 1974
138 LAVANDIN OIL 7.1 a Feb 2000
139 LAVENDER OIL 7.1 a Feb 2000
140 LEAD METALLIC 7.1 a ‑
141 LEPIDOPTEROUS SEX PHEROMONES 1 a Nov 1990
142 LIMONENE (DIPENTENE) 7.1 a Jun 2002
143 LINOLEIC ACID 7.1 a Oct 2005
144 LINSEED FATTY ACIDS 2.1 a Aug 1990
145 LINURON 1 a Feb 1990
146 LIQUORICE, DEGLYCYRRHISINISED 7.1 a May 1999
147 MAGNESIUM HYDROXIDE 7.1 a Jun 2021
148 MALEIC HYDRAZIDE 1 a Nov 1992
149 MANGANESE DIOXIDE 1 b May 1999
150 MEGASPHAERA ELSDENII strain 41125 2.4 a Sep 2013
151 MESOSULFURON‑METHYL 1.1 a Feb 2002
152 METARHIZIUM ANISOPLIAE 4.2 b Feb 2000
153 METARHIZIUM ANISOPLIAE 1.10 a Jun 2003
154 METCAMIFEN 1.1 a Feb 2020
155 METHOPRENE 1 a Aug 1987
156 METHOXYFENOZIDE 1 a Nov 2000
157 METHYL ACETATE 7.7 a ‑
158 METHYL BENZOQUATE 2.3 d Nov 1974
159 1‑METHYLCYCLOPROPENE 1.6 a Jun 2003
160 METHYL p‑HYDROXYBENZOATE 7.9 a Nov 1974
161 METSULFURONMETHYL 1.1 a Nov 1985
162 MYRISTIC ACID 7.1 a Oct 2005
163 NAPROPAMIDE 1 a Aug 1987
164 NAPTHYL ACETAMIDE 1.6 a Nov 1974
165 NEROLI OIL 7.1 a Feb 2000
166 NICARBAZIN 2.3 d Jun 1969
167 NISIN 3.2 a Jun 2003
168 NORFLURAZON 1.1 a Nov 1983
169 NOVALURON 1 a Nov 2000
170 NUCLEAR POLYHEDROSIS VIRUS of Helicoverpa armigera occlusion bodies 1.2 a Feb 2004
171 OCTYL ALCOHOLS 7.1 a Nov 1974
172 OLEIC ACID 7.1 a Oct 2005
173 ORANGE OIL, SWEET 7.1 a Aug 2000
174 OXABETRINIL 1 a Feb 1987
175 OXATHIAPIPROLIN 1.3 a Jun 2016
176 OXYFLUORFEN 1 a May 2001
177 PALMAROSA OIL 7.1 a Feb 2000
178 PALMITIC ACID 7.1 a Oct 2005
179 PATCHOULI OIL 7.1 a Feb 2000
180 PECTINASE derived from Aspergillus niger 2.4 a Feb 2005
181 PEGBOVIGRASTIM 2.1 a Jun 2017
182 PENCYCURON 1 a Aug 1994
183 PENTADECANOIC ACID 7.1 a Oct 2005
184 PEPPERMINT OIL 7.1 a Feb 2000
185 PHENMEDIPHAM 1.1 a May 1989
186 D‑PHENOTHRIN 7.5, 1.2 a Feb 1982
187 PHYTASE 2.4 a Feb 1996
188 PICLORAM 1 a Aug 1987
189 PICOLINAFEN 1 a May 2000
190 PIMELIC ACID 7.1 a Oct 2005
191 PIPERONYL BUTOXIDE 7.5 a Aug 1991
192 POLOXALENE 7.1 a Nov 1974
193 POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC) 4.1 a Nov 1997
194 POLYHEDROSIS VIRUS of Helico zea occlusion bodies 1 a Nov 1996
195 POLY (GNRF) OVALBUMIN 2 a Feb 1990
196 POLYSORBATE 20 1 a May 2001
197 PORCINE SOMATOTROPHIN 2 c Nov 1991
198 POTASSIUM SORBATE 1.3 a Oct 2004
199 POTASSIUM BICARBONATE 1 a Jun 2004
200 PROPYL ACETATES 7.1 a ‑
201 PROPYLENE GLYCOL 7.1 a Nov 1974
202 2‑PROPYLENE GLYCOL 1‑MONOMETHYL ETHER 4 a Nov 1987
203 PROTHIOCONAZOLE 1.3.1 a Jun 2005
204 PSEUDOMONAS FLUORESCENS 1.8 a May 1985
205 PYDIFLUMETOFEN 1.3 a Feb 2018
206 PYRIMETHANIL 1 a Feb 1996
207 PYRIPROXYFEN 1 a Aug 1994
208 QUASSIA 6, 2.1 d Nov 1974
209 QUINOXYFEN 1.3 a Nov 2001
210 RHIZOBIUM RHIZOGENES 1 b Nov 1989
211 ROSEMARY OIL 7.1 a Feb 2000
212 SAGE OIL (Spanish) 7.1 a Feb 2000
213 SANDALWOOD OIL 7.1 a Feb 2000
214 SEAWEED & UNFRACTIONED SEAWEED EXTRACTS 1.5 d Feb 1985
215 SILVER OXIDE 7.14 b Jun 2018
216 SIMAZINE 1.1 a Nov 1987
217 SODIUM BICARBONATE 1 a Jun 2004
218 SODIUM PROPIONATE 1.3 a Oct 2004
219 STERIC ACID 7.1 a Oct 2005
220 STREPTOMYCES LYDICUS WYEC 108 1.3 a Oct 2016
221 SUCRALFATE 6.8 a Aug 1982
222 SULESOMAB 6.1 b Jun 2002
223 SULFOSULFURON 1 a Feb 1998
224 SULPHATED POLYSACCHARIDES 7.1 a ‑
225 TANNIC ACID 7.1 a Dec 1965
226 TANNIC ACID/BENZYL ALCOHOL PRODUCT 7.1 a Nov 1993
227 TERBACIL 1 a Aug 1987
228 THAUMATIN 3.2 a Nov 1990
229 THIDIAZURON 1 a Nov 1989
230 TIAFENACIL 1 a June 2019
231 TRIASULFURON 1 a Feb 1988
232 TRICHODERMA HARZIANUM 1 a May 1996
233 (Z)‑9‑TRICOSENE 1 a Aug 1991
234 TRIETHYLENE GLYCOL 7.1 a Nov 1974
235 TRIFLOXYSULFURON 1.1 a Feb 2002
236 TRIFLURALIN 1 a Aug 1990
237 TRIFORINE 1 a Aug 1987
238 ULOCLADIUM OUDEMANSII 1.10 a Oct 2003
239 UREA 7.1 a Nov 1974
240 13C‑UREA 6.1 a May 2001
241 VETIVER OIL 7.1 a Feb 2000
242 VINYL ETHER 6 b Nov 1987
243 VITAMIN K 6.9, 2.8 a Jul 1963
244 XANTHOPHYLL (lutein) 7.1 a Nov 1974
245 XYLANASE derived from Aspergillus niger 2.4 a Feb 2005
246 YLANG YLANG OIL 7.1 a Feb 2000
247 ZINC NAPHTHENATE 1.3 a ‑
Appendix C—Blank
Note 1: Appendix C is intentionally blank.
Note 2: Appendix C previously included poisons now included in Schedule 10.
Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8
Note: See section 64.
1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner
A poison specified in the following table may be supplied for human use only by, on the prescription or order of, an authorised medical practitioner.
| 1 | CANNABIS for human use |
| 2 | CLOMIFENE for human use |
| 3 | CLOZAPINE for human use |
| 4 | CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use |
| 5 | CYCLOFENIL for human use |
| 6 | DINOPROST for human use |
| 7 | DINOPROSTONE for human use |
| 8 | FOLLITROPIN ALFA (recombinant human follicle‑stimulating hormone) for human use |
| 9 | FOLLITROPIN BETA (recombinant human follicle‑stimulating hormone) for human use |
| 10 | FOLLITROPIN DELTA (recombinant human follicle‑stimulating hormone) for human use |
| 11 | LUTEINISING HORMONE for human use |
| 12 | NABIXIMOLS for human use |
| 13 | SODIUM OXYBATE for human use |
| 14 | TETRAHYDROCANNABINOLS for human use |
| 15 | TERIPARATIDE for human use |
| 16 | UROFOLLITROPIN (human follicle‑stimulating hormone) for human use |
2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist
A poison specified in the following table may be supplied for human use:
(a) only by, or on the prescription or order of, a specialist physician or a dermatologist; and
(b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician or dermatologist has:
(ii) if the poison is acitretin or etretinate—advised the patient to avoid becoming pregnant during or for a period of 36 months after completion of treatment; and
(iii) if the poison is bexarotene, isotretinoin or thalidomide—advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.
| 1 | ACITRETIN for human use |
| 2 | BEXAROTENE for human use |
| 3 | ETRETINATE for human use |
| 4 | ISOTRETINOIN for human oral use |
| 5 | THALIDOMIDE for human use |
3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act
A poison specified in the following table may be supplied only by, or on the prescription or order of, a medical practitioner for whom an approval or authority under section 19 of the Act that covers the poison is in force.
| 1 | DRONABINOL (delta‑9‑tetrahydrocannabinol) |
4 Poisons available only from or on the order of a specialist physician
A poison specified in the following table may be supplied:
(a) only by, or on the prescription or order of, a specialist physician; and
(b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician has:
(ii) advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.
| 1 | LENALIDOMIDE |
| 2 | POMALIDOMIDE |
| 3 | RIOCIGUAT for human use |
| 4 | TRETINOIN for human oral use |
5 Poisons for which possession without authority is illegal
The following table specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription).
| 1 | ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4 |
| 2 | ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4 |
| 3 | AOD‑9604 (CAS No. 221231‑10‑3) |
| 4 | BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8 |
| 5 | CJC‑1295 (CAS No. 863288‑34‑0) |
| 6 | DARBEPOETIN |
| 7 | DEXTROPROPOXYPHENE |
| 8 | N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) |
| 9 | EPHEDRINE |
| 10 | EPOETINS |
| 11 | ERYTHROPOIETIN |
| 12 | ERYTHROPOIETINS except when separately specified in this Appendix |
| 13 | FIBROBLAST GROWTH FACTORS |
| 14 | FOLLISTATIN |
| 15 | GLUTETHIMIDE |
| 16 | GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4 |
| 17 | GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4 |
| 18 | GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6) |
| 19 | GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4 |
| 20 | HEXARELIN |
| 21 | IBUTAMOREN |
| 22 | INSULIN‑LIKE GROWTH FACTORS |
| 23 | IPAMORELIN |
| 24 | NICOTINE |
| 25 | PERAMPANEL for human use |
| 26 | PHENTERMINE |
| 27 | PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE‑2) (GHRP‑2)) |
| 28 | PSILOCYBINE |
| 29 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4 |
| 30 | SOMATROPIN (human growth hormone) |
| 31 | STENABOLIC (SR9009) and other synthetic REV‑ERB agonists |
| 32 | TB‑500 |
| 33 | THYMOSIN BETA 4 (THYMOSIN β4) |
| 34 | TIANEPTINE |
| 35 | VADADUSTAT |
6 Poisons available for human use only from or on the prescription or order of a specialist physician
A poison specified in the following table may be supplied for human use:
(a) only by, or on the prescription or order of, a specialist physician; and
(b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician has:
(ii) advised the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.
| 1 | AMBRISENTAN for human use |
| 2 | BOSENTAN for human use |
| 3 | ENZALUTAMIDE for human use |
| 4 | MACITENTAN for human use |
| 5 | SITAXENTAN for human use |
7 Poisons available for human use only from or on the prescription or order of a dermatologist
A poison specified in the following table may be supplied for human use only by, or on the prescription or order of, a dermatologist.
| 1 | ALEFACEPT for human use |
8 Poisons available for initial treatment of a patient only if authorised by certain health practitioners
HYDROXYCHLOROQUINE may be supplied, for human use, for the initial treatment of a patient only if that treatment is authorised by:
(a) a medical practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in any of the following specialties or fields of specialty practice:
(i) dermatology;
(ii) emergency medicine;
(iii) intensive care medicine;
(iv) paediatrics and child health;
(v) physician; or
(b) a dental practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in the specialty of oral medicine.
9 Poisons which must be stored in a locked container to prevent unauthorised access
The following table specifies poisons that must be stored in a locked container to prevent unauthorised access.
| 1 | PENTOBARBITAL in injectable preparations |
10 Poisons available only when prescribed or authorised in certain circumstances
N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human use may be supplied only for the treatment of post-traumatic stress disorder:
(a) if MDMA is prescribed, or its supply is authorised, by a medical practitioner:
(i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and
(ii) for whom an authority under subsection 19(5) of the Act that covers MDMA is in force; or
(b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.
PSILOCYBINE in preparations for human use may be supplied only for the treatment of treatment-resistant depression:
(a) if psilocybine is prescribed, or its supply is authorised, by a medical practitioner:
(i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and
(ii) for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force; or
(b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.
Appendix E—First aid instructions for poisons
Note: See section 31.
1 Standard statements for first aid instructions
For the purposes of the table in clause 3, the statement code specified in column 2 of an item of the following table represents:
(a) the statement specified in column 3 of the item; or
(b) a different statement that has the same intent as the statement specified in column 3 of the item.
1 Basic A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).
2 Basic Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
3 General G1 Urgent hospital treatment is likely to be needed.(Note ‑ the words “at once” to be added to instruction A).
4 General G2 If swallowed, give activated charcoal if instructed.(Note ‑ the words “at once” to be added to instruction A).
5 General G3 If swallowed, do NOT induce vomiting.
6 General G4 Immediately give a glass of water.
7 General G5 Avoid giving milk or oils.
8 General G6 If sprayed in mouth, rinse mouth with water.
9 Eyes E1 If in eyes wash out immediately with water.
10 Eyes E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.
11 Respiratory system R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
12 Respiratory system R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth‑to‑mouth resuscitation. To protect rescuer, use air‑viva, oxy‑viva or one‑way mask. Resuscitate in a well‑ventilated area.
13 Skin S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
14 Skin S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
15 Skin S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
16 Skin S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
17 Skin S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).
18 Special Purpose SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.
2 Poisons information centre contact information in statements
A statement required for a poison that includes a reference to a Poisons Information Centre must include:
(a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and
(b) immediately following the reference to a Poisons Information Centre:
(i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or
(ii) the telephone number for another poisons information centre:
(A) that is attended by adequately trained staff for 24 hour emergency poisons information; and
(B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.
Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.
3 First aid instructions for poisons
(1) For the purposes of subsection 31(1), and subject to subclause (2), the statement represented by each statement code specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.
(2) A statement required for a poison must:
(a) be modified for its use in relation to that poison as appropriate for the poison (for example if the poison is combined with other substances (whether toxic or non‑toxic) or is in a particular physical form or presentation); and
(b) if the statement refers to a Poisons Information Centre—comply with clause 2.
Poisons that must be labelled with first aid instructions
Item Column 1 Poison Column 2 Statement code
1 ACETIC ACID A, G3, E2, S1
2 ACETIC ANHYDRIDE A, G3, E2, S1
3 ACETONE A, G3
4 ACROLEIN A, G1, G2, G3, E2, R2, S2
5 ALKALINE SALTS A, G3, E2, S1
6 ALKYL NITRITES A
7 AMIDOPROPYL BETAINES—in cosmetic wash‑off preparations when included in Schedule 6 E1
8 AMIDOPROPYL BETAINES—in other preparations when included in Schedule 6 E1, S1
25 ANHYDRIDES, organic acid, for use as curing agents for epoxy resins A, G3, E1, S1
26 ANILINE A, E2, R1, S1
27 ANISE OIL A, G3
28 ANITMONY CHLORIDE A, E2, S2
29 ANTIMONY COMPOUNDS, except antimony chloride A
30 ARBUTIN when included in Schedule 6 A, G2, G3, E2, R2, S1
31 AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6 A, E1
32 AZO DYES (derivatives by diazotisation) A
33 BARIUM SALTS, except barium sulfate A
34 BASIC RED 76 A
35 BASIL OIL A, G3
36 BAY OIL A, G3
37 BENZALKONIUM CHLORIDE—when included in Schedule 5 A, G3, E2
38 BENZALKONIUM CHLORIDE—when included in Schedule 6 A, G3, E2, S1
39 BENZENE A, G3, E1, R1, S1
40 1,2‑BENZENEDIOL (Catechol) A, E1, S1
41 BENZOYL PEROXIDE—above 20% A, E2, S1
42 BENZOYL PEROXIDE—above 10% up to 20% A, E1
43 BENZOYL PEROXIDE—10% or less A
44 BERGAMOT OIL A, G3
45 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 A
46 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 A, G3, E2, S5
47 1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE E1, S1
48 BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER A, E1
49 BORAX A
50 BORIC ACID A
51 BORON TRIFLUORIDE—when included in Schedule 5 A
52 BORON TRIFLUORIDE—when included in Schedule 6 or 7 A, G3, E2, S5
53 BROMOFORM A, G3, E2, R1, S2
54 BRUCINE A, G1, G2, G3, R2
55 2‑BUTOXYETHANOL and its acetates A, E2, S1
56 n‑BUTYL ALCOHOL A, E1, S1
57 BUTYL NITRITE A
58 CADMIUM COMPOUNDS A
59 CAJUPUT OIL A, G3
60 CAMPHOR A, G1, G3, G5
61 CARBAMIDE PEROXIDE—more than 9% up to 60% A, G3, E2, S1
62 CARBAMIDE PEROXIDE—more than 60% A, G1, G3, G4, E2, S1
63 CARBON DISULFIDE A, G3, E2, R1, S2
64 CARBON TETRACHLORIDE A, G3, E1, R1, S1
65 CASSIA OIL A, G3
66 CHLORINATING COMPOUNDS, except when separately specified—containing above 4% and below 10% of available chlorine A, G3, E1, S1
67 CHLORINATING COMPOUNDS, except when separately specified—containing 10% or more of available chlorine A, G3, E2, S1
68 CHLORIDE (gas) A, E1, R1
69 CHLOROACETAMIDE A
70 CHLOROCRESOL A, G3, E2, S2
71 2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL A, S1
72 CHLOROFORM A, G3, E1, R1, S1
73 CHROMATES A, G3, E2, S1
74 CHROMIUM TRIOXIDE A, G3, E2, S1
75 CHRYSOIDINE BASE A, S1, E1
76 CINEOLE A, G1, G3
77 CINNAMON BARK OIL A, G3
78 CINNAMON LEAF OIL A, G3
79 CLIMBAZOLE A
80 CLOVE OIL A, G1, G3, E2
81 COCOYL GLYCINATE E1
82 COPPER SULFATE A, G3, E2, S1
83 CREOSOTE A, G3, E2, S1
84 CRESOLS A, G3, E2, S3
85 CRESOLS in pressurised spray packs A, G6, E1, S1
86 CYANIDES A, G1, E1, R2
87 CYANOACRYLIC ACID ESTERS A
88 CYANURIC ACID A
89 CYCLOHEXANONE PEROXIDE A, G3, E2, S1
90 CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) A, E2, S1
299 SODIUM NITRITE—when included in Schedule 7 A, G1, G3
300 SODIUM NITRITE—when included in Schedule 5 or 6 A, G3
301 SODIUM PERCARBONATE—when included in Schedule 5 A, G3, S1
302 SODIUM PERCARBONATE—when included in Schedule 6 A, G3, E2, S1
303 SODIUM PERSULFATE A, G3, E2
304 SODIUM STANNATE A, E1
305 SODIUM SULFIDE A, G3, E2, S1
306 SODIUM TRICHLOROACETATE A
307 STRYCHNINE A, G1, G2, G3, R2
308 STYRENE A, G3, S1, E1
309 SULCOFURON A
310 SULFAMIC ACID A, G3, E2, S1
311 SULFURIC ACID A, G3, E2, S1
312 TERPENES, chlorinated A, G3
313 TETRACHLOROETHANE A, G3, E1, R1, S1
314 TETRACHLOROETHYLENE A, G3, E2, R1, S1
315 THIOUREA A
316 THUJONE A, G3
317 THYME OIL A, G3
318 o‑TOLIDINE A
319 TOLUENE—above 75% A, G3, E1, R1, S1
320 TOLUENE—75% and below A, G3
321 TOLUENE—in pressurised spray packs A
322 TOLUENEDIAMINES—in hair dyes A, E1
323 TOLUENEDIAMINES—in other preparations A, G1, G3, E1, S1
324 TRICHLOROACETIC ACID A, G3, E2, S1
325 TRICHLOROACETIC ACID ALKALI SALTS A
326 1,1,1‑TRICHLOROETHANE A, G3, E1, R1, S1
327 TRICHLOROETHYLENE A, G3, E1, R1, S1
328 TRICHLOROISOCYANURIC ACID A, G3, E1, S1
329 TRIETHYL PHOSPHATE A, E1
330 TRIFLUOROMETHANESULFONIC ACID A, G3, E2
331 TRIISOPROPANOLAMINE LAURYL ETHER SULFATE A, E1, S1
332 TROLAMINE A, G3, E1, S1
333 TURPENTINE (mineral) A, G3
334 TURPENTINE OIL (vegetable) A, G3, E2
335 VINYL ACETATE MONOMER A, R1
336 WHITE SPIRIT A, G3
337 XYLENE—above 75% A, G3, E1, R1, S1
338 XYLENE—75% and below A, G3
339 XYLENE—in pressurised spray packs A, G6, E1, S1
340 XYLENOLS in pressurised spray packs A, E1
341 ZINC CHLORIDE A, G3, E2, S1
342 ZINC SULFATE A, G3, E2, S1
Appendix F—Warning statements and general safety directions for poisons
Note: See sections 29 and 30, subsection 33(2) and section 42.
1 Warning statements
For the purposes of the table in clause 4 of this Appendix and the table in clause 2 of Appendix L, the item number of an item of the following table represents the warning statement specified in column 1 of the item.
Note: See section 30.
Warning statements
Item Column 1 Warning statement
1 Highly corrosive.
2 Corrosive.
3 Corrosive liquid.
4 Strongly alkaline.
5 Irritant.
6 May cause cancer.
7 WARNING – Causes birth defects.
8 WARNING – May be fatal to children.
9 Can be fatal to children if sucked or swallowed.
10 May produce severe burns.
11 WARNING – Vapour may be harmful.
12 Vapour is harmful to health on prolonged exposure.
13 May be fatal if inhaled, swallowed or absorbed through skin.
14 Dust will irritate and burn eyes, nose and skin.
15 Liquid will cause burns.
16 Forms dangerous gas near radiators or naked flames.
17 Contact with eyes even for short periods can cause blindness.
18 Product will irritate the eyes, nose, throat and skin.
19 WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use.
20 May give off dangerous gas if mixed with other products.
21 WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
22 Highly reactive oxidising chlorine compound.
23 May cause fire or explosion.
24 For external washing only. Rinse skin thoroughly after use.
25 Do not use on broken skin. Wash hands thoroughly after use.
26 (Powder) (and) (concentrated solutions) are dangerous if swallowed.
27 Not for therapeutic use.
28 (Over) (Repeated) exposure may cause sensitisation.
29 If congestion persists, consult your doctor or pharmacist.
30 WARNING – Do not use on face or on anal or genital areas.
31 WARNING – Do not use on face or on anal or genital areas except on doctor’s advice.
32 This preparation should be part of an overall treatment plan regularly assessed with your doctor.
33 Do not take for periods longer than four weeks except on medical advice.
34 WARNING – This medication may be dangerous when used in large amounts or for a long time (period).
35 CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.orCAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.
36 For use under medical supervision only.
37 Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.
38 CAUTION – Do not use for children under 2 years unless a doctor has told you to.
39 This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.
40 This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.
41 Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.
42 WARNING – Overuse may stain the skin or mouth.
43 Use of this product is not necessary in areas supplied with fluoridated water.
44 WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.
45 WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.
46 WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).
47 WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
48 WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
49 WARNING – Do not mix with other medication except on veterinarian’s advice.
50 Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.
51 Irritant to skin, eyes, mucous membranes and upper respiratory tract.
52 Breathing vapour or spray mist is harmful and may cause an asthma‑like reaction.
53 CAUTION – (Name of substance) should not be used by pregnant women.
54 Seek medical advice before first course of treatment.
55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.
56 WARNING – Can cause elevated blood pressure and interact adversely with other medication.
57 Not to be applied to infants under 12 months of age unless on doctor’s advice.
58 Highly reactive oxidising bromine and chlorine compound.
59 May cause allergy.
60 Do not mix with detergents or other chemicals.
61 WARNING ‑ Can react with other medicines. Ask your doctor or pharmacist before taking.
62 Do not use if pregnant.
63 See a doctor if you are pregnant or diabetic.
64 See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.
65 If getting better, keep using for (Insert number of days as per approved Product Information) days.
66 See a doctor if problem returns.
67 Do not use if pregnant or likely to become pregnant.
68 If symptoms persist beyond 5 days consult a doctor (or) (dentist).
69 If symptoms recur within two weeks of completing the course, consult a doctor.
70 Use only under medical supervision if you are taking other medicines.
71 Do not use during the last three months of pregnancy.
72 Do not use in the eyes.
73 Do not use for acne.
74 Do not use under waterproof bandages unless a doctor has told you to.
75 Do not use for more than 7 days unless a doctor has told you to.
76 Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.
77 WARNING ‑ May cause birth defects.
78 Attacks skin and eyes.
79 Will irritate eyes.
80 WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury.
81 (Intentionally blank)
82 (Intentionally blank)
83 This paint is dangerous to health, even when dry.For industrial use only.Do not use on toys or furniture.Do not use on, in or around the home.
84 Breathing the vapour is dangerous.Provide adequate ventilation during application.Do not use in the presence of a naked flame.Do not smoke.
85 This paint contains lead and is dangerous to health, even when dry.For industrial use only.Do not use on toys or furniture.Do not use for painting any building or fixed structure.Do not use where contact with food or drinking water is possible.
86 This tinter contains lead.Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.
87 (Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.
88 This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.
89 Application to skin may increase sensitivity to sunlight.
90 This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.
91 CAUTION – Total iodine intake may exceed recommended level when taking this preparation.
92 WARNING – Contains iodine ‑ do not take when pregnant except on physician’s advice.
93 Causes severe burns, which are not likely to be immediately painful or visible.
94 WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.
95 CAUTION – Do not use for children under 12 years unless a doctor has told you to.
96 CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.
97 Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.
98 Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.
99 If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.
100 Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.
101 Don’t use [this product/name of the product]:If you have a stomach ulcer.In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]If you are allergic to (name of substance) or anti‑inflammatory medicines.
102 Unless a doctor has told you to, don’t use [this product/name of the product]:For more than a few days at a time.With other medicines containing aspirin or other anti‑inflammatory medicines.If you have asthma.In children under 12 years of age.In children 12‑16 years of age with or recovering from chicken pox, influenza or fever.If you are pregnant.
103 See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]
104 Unless a doctor has told you to, don’t use [this product/name of the product]:For more than a few days at a time.With other medicines containing (name of substance) or other anti‑inflammatory medicines.If you have asthma.If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]
105 Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.
106 Contains formaldehyde.
107 Not recommended for children under twelve years of age.
108 Breathing of solder fumes is harmful and may cause asthma or sensitisation.
109 See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI).
110 See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed.
111 Do not use if breastfeeding or planning to breastfeed.
112 WARNING – May cause irreversible nerve damage if inhaled.
2 Safety directions—general
For the purposes of the table in clause 4, the item number of an item of the following table represents the safety direction specified in column 1 of the item.
12 Do not allow product to come into contact with other chemicals, especially acids.
13 Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.
14 Do not allow to get damp.
15 Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
16 Store and transport in an upright container.
17 Do not mix with other chemicals.
18 Do not mix with different types of chlorinating chemicals.
19 Use clean containers for dispensing.
20 Mix with water only.
21 Do not add water to product ‑ add product to water, but in case of fire drench with water.
22 In case of spillage flush with large quantities of water.
23 Keep away from heat, sparks and naked flames.
24 Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.
25 Avoid contact with food.
26 Avoid contact with clothing.
27 Wear a positive‑pressure air‑supplied full‑face respirator whilst spraying and until spray mist has been effectively dispersed.
28 Do not mix with hot water.
29 Obtain a supply of calcium gluconate gel.
30 (Intentionally blank)
31 Do not use on broken skin.
32 Do not use under occlusive dressing.
33 Mix strictly according to instructions.
34 May cause fire if it comes into contact with other chemicals, paper or other flammable materials.
35 Wash gloves thoroughly, immediately after use.
36 Protect cuticles with grease or oil.
37 Avoid breathing solder fumes.
38 Do not intentionally inhale contents.
3 Poisons information centre contact information in statements
A statement required for a poison that includes a reference to a Poisons Information Centre must include:
(a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and
(b) immediately following the reference to a Poisons Information Centre:
(i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or
(ii) the telephone number for another poisons information centre:
(A) that is attended by adequately trained staff for 24 hour emergency poisons information; and
(B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.
Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.
4 Poisons that must be labelled with warning statements and safety directions
(1) For the purposes of subsections 29(1) and 30(1), and subject to subclauses (2) and (3), the following are required for a poison specified in column 1 of an item of the following table:
(a) the warning statement represented by each item number specified in column 2 of the item;
(b) the safety direction represented by each item number specified in column 3 of the item.
(2) A warning statement or safety direction required for a poison must:
(a) be completed or modified for its use in relation to that poison if the statement or direction indicates that such completion is required or such modification is appropriate; and
(b) if the statement includes a reference to a Poisons Information Centre—comply with clause 3.
Note: For paragraph (a), for example:
(a) a statement or direction may require completion by including the name of the poison; and
(b) a statement or direction may indicate that modification is appropriate by including different options for the text, or by stating that certain text is not needed in certain circumstances.
(3) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).
Poisons that must be labelled with warning statements and safety directions
Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number
1 ACETIC ACID in concentrations of 80% or more except when included in Schedule 2 2 1, 4, 8
2 ACETIC ANHYDRIDE 2 1, 4, 8
3 ACETONE in concentrations greater than 75% 1, 4, 8
4 ACITRETIN—for oral use 7, 62, 76
5 ACITRETIN—for topical use 62, 77
6 ADAPALENE for topical use 62, 77
7 ALCLOMETASONE when included in Schedule 3 38, 72, 73, 74, 75
8 ALKALINE SALTS 4 1, 4
9 AMBRISENTAN 7, 62, 76
10 AMINES used as curing agents for epoxy resins 1, 3, 4, 5, 8
19 AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20% ammonia except in smelling salts 4 1, 4, 8
20 AMMONIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34
21 ANHYDRIDES, organic acid, for use as curing agents for epoxy resins 1, 3, 4, 5, 8
22 ANILINE 13 1, 4, 8
23 ANTIHISTAMINES not separately specified in this Appendix except the following:(a) dermal, ocular, parenteral and paediatric preparations;(b) oral preparations of astemizole, azelastine, bilastine, cetirizine, desloratadine, fexofenadine, loratadine, or terfenadine;(c) nasal preparations of azelastine or olopatadine;(d) preparations for the treatment of animals 39 or 40
24 ARBUTIN when included in Schedule 6 45 1, 4
25 AROMATIC EXTRACT OILS 1, 3, 4, 5, 6
26 ASPIRIN—for inhibition of platelet aggregation 36
27 ASPIRIN—in sustained release preparations containing 650 mg or more of aspirin 36
28 ASPIRIN—in other preparations 101, 102, 103
29 ASTEMIZOLE 61
30 ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis 63, 64, 69, 75, 109, 110
31 ASTODRIMER SODIUM—for the prevention of recurrent bacterial vaginosis 63, 75, 109, 110
32 AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6 67
33 AZOCYCLOTIN 48
34 AZO DYES (derivatives by diazotisation) 6 5
35 BASIC RED 76 5
36 BENOMYL 46
37 BENZENE 12 1, 4, 9
38 1,2‑BENZENEDIOL (Catechol) 51, 59 1, 4, 8
39 BENZOYL PEROXIDE—when included in Schedule 2 55
40 BENZOYL PEROXIDE—when included in Schedule 5 1, 4, 8
41 BERGAMOT OIL 89
42 BERYLLIUM 1, 4, 8
43 BEXAROTENE—for human use 7, 62, 76
44 BEXAROTENE—for topical use 62, 77
45 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 1, 4
46 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35
51 BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 5 2 1, 4
52 BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35
53 BOSENTAN 7, 62, 76
54 BROMOFORM 1, 4, 8
55 2‑BUTOXY‑2'‑THIOCYANODIETHYL ETHER 1, 4, 8
56 2‑BUTOXYETHANOL and its acetates 1, 4, 8
57 n‑BUTYL ALCOHOL 5 2, 4, 8
58 CAMPHOR—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents 9
59 CAMPHOR—in other forms 9 1
60 CANNABIDIOL when included in Schedule 3 67, 111
61 CARBAMIDE PEROXIDE—more than 9% up to 30% 5 1
62 CARBAMIDE PEROXIDE—more than 30% up to 60% 5 2
63 CARBAMIDE PEROXIDE—more than 60% 2 2, 4
64 CARBON DISULFIDE 12 1, 4, 8, 9, 23
65 CARBON TETRACHLORIDE 12 1, 4, 8, 9
66 CASSIA OIL 4
67 CHLORINATING COMPOUNDS—in household cleaning or bleaching preparations 20
68 CHLORINATING COMPOUNDS—in preparations containing less than 10% of available chlorine 11 1, 4, 10
69 CHLORINATING COMPOUNDS—in liquid preparations containing 10% or more of available chlorine 3, 18 1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26
70 CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine 10, 18, 22, 23 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
71 CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code 10, 18, 22 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 26
72 CHLORINATING COMPOUNDS—in compressed block or tablets containing 10% or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid 10, 22, 23 12, 13, 14, 15, 17, 18, 19, 21
73 CHLORINATING COMPOUNDS—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid 10, 22 12, 13, 14, 15, 17, 18, 19, 21
74 CHLOROACETAMIDE 28 4
75 2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL 28 4
76 CHLOROFORM when included in Schedule 6 1, 4, 8
77 alpha‑CHLOROHYDRIN 13, 51 1, 4, 8, 9
78 CHROMATES (including dichromates) of alkali metals or ammonia 1, 4, 8
79 CHROMIUM TRIOXIDE 2, 14, 15, 23 1, 4, 8, 13
80 CIMETIDINE when included in Schedule 3 70, 96
81 CINNAMON BARK OIL 4
82 CLOBETASONE when included in Schedule 3 72, 73, 74, 75, 95
83 CLOTRIMAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66
84 CLOVE OIL 1
85 CYANIDES when included in Schedule 7 13 4, 8
86 CYANURIC ACID 1, 4, 8
87 CYCLOHEXANONE PEROXIDE 1, 4, 8
88 CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) 2, 10, 78 1, 4, 5, 35
97 DICHLOROISOCYANURATES—in household cleaning or bleaching preparations 20
98 DICHLOROISOCYANURATES—in preparations containing less than 10% of available chlorine 11 1, 4, 10
99 DICHLOROISOCYANURATES—in liquid preparations containing 10% or more of available chlorine 3, 18 1, 4, 6, 8, 10,15, 16, 17, 18, 19, 20, 22, 26
100 DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine 10, 18, 22, 23 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
101 DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code 10, 18, 22 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26
102 DICHLOROISOCYANURATES—in anti‑bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate 60
103 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only 10, 22, 23 12, 13, 14, 15, 17, 18, 19, 21
104 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only 10, 22 12, 13, 14, 15, 17, 18, 19, 21
105 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage 10, 22, 23 12, 13, 14, 15, 17, 18, 21
106 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use 5 1, 4, 7, 12
107 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage 10, 22 12, 13, 14, 15, 17, 18, 21
108 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use 5 1, 4, 7, 12
226 MICONAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66
227 MISOPROSTOL 53
228 MONOETHANOLAMINE when included in Schedule 5 5 1, 4
229 MONOETHANOLAMINE when included in Schedule 6 2, 11, 18 1, 4, 8
230 NAPHAZOLINE in nasal preparations for topical use 29
231 NAPHTHALENE—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents 9, 105
232 NAPHTHALENE—in other forms 9, 105 1
233 1,5‑NAPHTHALENEDIOL 28 1
234 2,7‑NAPHTHALENEDIOL 28 1, 3
235 1‑NAPHTHOL 28 1
236 NAPROXEN 101, 104
237 NICOTINE except when in tobacco 1, 4
238 NITRIC ACID—75% or less HNO3 2 1, 4
239 NITRIC ACID—more than 75% HNO3 2 1, 4, 8
240 NITROBENZENE 1, 4, 8
241 3‑NITRO‑p‑HYDROXYETHYLAMINOPHENOL 28
242 NITROPHENOLS 1, 4
243 NITROPRUSSIDES in aerosols 84 8
244 NITROUS OXIDE 112 38
245 NIZATIDINE when included in Schedule 2 96
246 NORADRENALINE in metered aerosols 32
247 NYSTATIN in vaginal preparations when included in Schedule 3 54, 63, 64, 65, 66
248 ORANGE OIL (bitter) 89
249 ORCIPRENALINE in metered aerosols 32
250 OXALATES, metallic 4, 8
251 OXALIC ACID 2 4, 8
252 OXYMETAZOLINE in nasal preparations for topical use 29
253 OXYQUINOLINE (including salts and derivatives) when prepared for internal use 33
254 PAINT—first group paints 83
255 PAINT—second group paints 84
256 PALOVAROTENE 7, 62, 76, 111
257 PARACETAMOL 97 and/or 98, 99, 100
258 PENTACHLOROPHENOL 1, 4, 8
259 PERACETIC ACID 2 1, 4, 8
260 PERMANGANATES 2 24
261 2‑PHENOXYETHANOL 5 1
262 PHENOL and any other homologue of phenol 1, 4
263 PHENOL when included in Schedule 6 3, 51 2, 4, 8
Note 2: Appendix I previously included poisons now dealt with in Division 9 of Part 2.
Appendix J—Conditions for availability and use of certain poisons included in Schedule 7
Note: See subsection 62(6).
1 Conditions for supply of certain poisons included in Schedule 7
For the purposes of subsection 62(6), a poison included in Schedule 7 that is specified in column 1 of an item of the following table may be supplied:
(a) only to a person who is appropriately authorised or licensed under the law of the jurisdiction where the person will receive the poison; and
(b) if “a” appears in column 2 of the item—only for analytical or research purposes; and
(c) if “p” appears in column 2 of the item—only to a person who is authorised or licensed, under the law of the jurisdiction where the person will receive the poison, to possess and use the poison.
Conditions for supply of certain poisons included in Schedule 7
Item Column 1 Poison Column 2 Condition
1 ABAMECTIN
2 ACIBENZOLAR‑S‑METHYL
3 ACROLEIN
4 ACRYLONITRILE
5 ALACHLOR a
6 ALLYL ALCOHOL
7 4‑AMINOPROPIOPHENONE p
8 4‑AMINOPYRIDINE
9 ARPRINOCID a
10 ARSENIC p
11 AZOCYCLOTIN a
12 BENZENE
13 BIFLUORIDE
14 BORON TRIFLUORIDE
15 BRODIFACOUM
16 BROMADIOLONE
17 BROMINE
18 BRUCINE
19 CALCIFEROL
20 CARBADOX
21 CARBON TETRACHLORIDE
22 CARBONYL SULFIDE
23 CHLORDECONE a
24 CHLORDIMEFORM a
25 CHLORINE
26 CHLOROMETHIURON a
27 CHLOROPICRIN
28 4‑CHLORO‑o‑TOLUIDINE a
29 COLECALCIFEROL
30 COUMATETRALYL
31 CYANOGEN
32 CYHEXATIN a
33 4,4‑DIAMINODIPHENYLMETHANE
34 1,2‑DIBROMO‑3‑CHLOROPROPANE a
35 1,3‑DICHLOROPROPENE
36 DIFENACOUM
37 4‑DIMETHYLAMINOAZOBENZENE a
38 DINITROCRESOLS a
39 DINITROPHENOLS a
40 DINOSEB a
41 EPICHLOROHYDRIN
42 EPIDERMAL GROWTH FACTOR
43 ETACONAZOLE a
44 ETHYLENE DIBROMIDE a
45 ETHYLENE OXIDE
46 FLUOROACETAMIDE p
47 FLUOROACETIC ACID p
48 FOLPET
49 HALOFUGINONE
50 HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS a
51 HCB a
52 HYDROCYANIC ACID AND CYANIDES p
53 HYDROFLUORIC ACID
54 HYDROSILICOFLUORIC ACID
55 IODOMETHANE
56 MADURAMICIN
57 MERCURY
58 METHACRIFOS
59 METHOXYETHYLMERCURIC ACETATE a
60 METHOXYETHYLMERCURIC CHLORIDE
61 METHYL BROMIDE
62 4,4'‑METHYLENEBIS[2‑CHLOROANILINE]
63 MIREX a
64 MOLINATE
65 NICOTINE except when in tobacco
66 NITROFEN a
67 PHENYLMERCURIC ACETATE
68 PHOSPHIDE, metallic
69 PHOSPHINE
70 PROPYLENE OXIDE
71 PYRINURON a
72 STRYCHNINE p
73 SULCOFURON a
74 TETRACHLOROETHANE
75 2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE
76 THALLIUM p
77 o‑TOLIDINE
78 VINYL CHLORIDE
Appendix K—Human medicines required to be labelled with a sedation warning
Note: See subsection 33(2).
1 Human medicines required to be labelled with a sedation warning
The following table specifies poisons for the purposes of subsection 33(2).
Human medicines required to be labelled with a sedation warning
Item Column 1 Poison
1 ALIMEMAZINE
2 ALPRAZOLAM
3 AMISULPRIDE
4 AMITRIPTYLINE
5 AMOBARBITAL
6 ARIPIPRAZOLE
7 ASENAPINE
8 AZATADINE
9 BACLOFEN
10 BENZATROPINE
11 BREXPIPRAZOLE
12 BRIVARACETAM
13 BROMAZEPAM
14 BROMPHENIRAMINE
15 BUCLIZINE
16 BUPRENORPHINE
17 BUTOBARBITAL
18 CANNABIS except cannabidiol when included in Schedule 3 or 4
19 CETIRIZINE
20 CHLORAL HYDRATE
21 CHLORDIAZEPOXIDE
22 CHLORMETHIAZOLE
23 CHLORPHENAMINE
24 CHLORPROMAZINE
25 CLEMASTINE
26 CLOMIPRAMINE
27 CLONAZEPAM
28 CLONIDINE
29 CLORAZEPATE
30 CLOZAPINE
31 CODEINE.
32 CYCLIZINE
33 CYCLOBARBITAL
34 CYCLOSERINE
35 CYPROHEPTADINE
36 DANTROLENE
37 DESIPRAMINE
38 DEUTETRABENAZINE.
39 DEXCHLORPHENAMINE
40 DEXTROMORAMIDE
41 DEXTROPROPOXYPHENE
42 DIAZEPAM
43 DIFELIKEFALIN
44 DIFENOXIN
45 DIHYDROCODEINE
46 DIMENHYDRINATE
47 DIMETHINDENE
48 DIPHENHYDRAMINE
49 DIPHENOXYLATE
50 DIPHENYLPYRALINE
51 DOSULEPIN
52 DOXEPIN
53 DOXYLAMINE
54 DRONABINOL (delta‑9‑TETRAHYDROCANNABINOL)
55 DROPERIDOL
56 DULOXETINE
57 ESKETAMINE
58 ETHYLMORPHINE
59 FENFLURAMINE
60 FENTANYL
61 FLUNITRAZEPAM
62 FLUPENTIXOL
63 FLUPHENAZINE
64 FLURAZEPAM
65 GABAPENTIN
66 GEMCITABINE
67 GLUTETHIMIDE
68 GUANFACINE
69 HALOPERIDOL
70 HYDROCODONE
71 HYDROMORPHONE
72 HYDROXYZINE
73 IMIPRAMINE
74 LAMOTRIGINE
75 LEMBOREXANT.
76 LEVETIRACETAM
77 LEVOCABASTINE
78 LEVOCETIRIZINE
79 LORAZEPAM
80 LURASIDONE.
81 MAZINDOL
82 MEBHYDROLIN
83 MECLOZINE
84 MEDAZEPAM
85 MEPROBAMATE
86 MEPYRAMINE
87 MERCAPTAMINE
88 METHADONE
89 METHDILAZINE
90 METHOCARBAMOL
91 METHYLPHENOBARBITAL
92 MIANSERIN
93 MIDAZOLAM
94 MIRTAZAPINE
95 MORPHINE
96 NABIXIMOLS.
97 NALBUPHINE
98 NITRAZEPAM
99 NORMETHADONE
100 NORTRIPTYLINE
101 OLANZAPINE
102 OPIUM in any form except the alkaloids noscapine and papaverine
103 OXAZEPAM
104 OXYCODONE
105 PALIPERIDONE
106 PAPAVERETUM
107 PENTAZOCINE
108 PENTOBARBITAL
109 PERAMPANEL
110 PERICIAZINE
111 PERPHENAZINE
112 PETHIDINE
113 PHENELZINE
114 PHENIRAMINE
115 PHENOBARBITAL
116 PHENOPERIDINE
117 PHENYLTOLOXAMINE
118 PHOLCODINE
119 PIMOZIDE
120 PIZOTIFEN
121 PRAZEPAM
122 PREGABALIN
123 PROCHLORPERAZINE
124 PROMAZINE
125 PROMETHAZINE
126 PROTRIPTYLINE
127 QUETIAPINE
128 RETIGABINE
129 RISPERIDONE
130 ROTIGOTINE
131 RUFINAMIDE
132 RUPATADINE
133 SAFINAMIDE
134 SECBUTOBARBITAL
135 SECOBARBITAL
136 SELETRACETAM
137 SODIUM OXYBATE
138 STIRIPENTOL
139 SUVOREXANT
140 TAPENTADOL
141 TEMAZEPAM
142 TETRAHYDROCANNABINOLS except cannabidiol when included in Schedule 3 or 4
143 THENYLDIAMINE
144 THIETHYLPERAZINE
145 THIOPROPAZATE
146 THIORIDAZINE
147 THIOTHIXENE
148 TRABECTEDIN
149 TRAMADOL
150 TRANYLCYPROMINE
151 TRIFLUOPERAZINE
152 TRIMIPRAMINE
153 TRIPROLIDINE
154 ZIPRASIDONE
155 ZOLPIDEM
156 ZONISAMIDE
157 ZOPICLONE
Appendix L—Requirements for dispensing labels for medicines
Note: See subsection 33(1) and paragraph 40(b).
1 General
(1) This clause sets out requirements for the purposes of paragraph 40(b).
(2) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 mm in height.
(3) All symbols, numbers and words on a label must be in durable characters.
(4) The label on a container of a substance for therapeutic use must contain the following details:
(a) the name, address and telephone number of the dispenser supplying the substance;
(b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);
(c) adequate directions for use;
(d) the strength and form of the substance;
(e) the total quantity of the goods in the container;
(f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;
(g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;
(h) if the substance is a medicine for human use, the name of the person for whom it was dispensed; and
(i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.
(5) The label on a container of a medicine for human use, or a veterinary chemical, that is supplied on prescription must also include:
(a) the prescription reference number; and
(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and
(c) the directions for use set out in the prescription.
2 Additional warning statements for certain human medicines
(1) For the purposes of subsection 33(1), and subject to subclause (2), the warning statement represented by each item number specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.
Note: For the warning statements represented by the item numbers, see clause 1 of Appendix F.
(2) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).
Additional warning statements for certain human medicines
Item Column 1 Poison Column 2 Warning statement item number
1 ACITRETIN—for oral use 7, 62, 76
2 ACITRETIN—for topical use 62, 77
3 ADAPALENE—for oral use 7, 62, 76
4 ADAPALENE—for topical use 62, 77
5 AMBRISENTAN 7, 62, 76
6 BELUMOSUDIL 62, 77
7 BEXAROTENE—for oral use 7, 62, 76
8 BEXAROTENE—for topical use 62, 77
9 BOSENTAN 7, 62, 76
10 DIENESTROL 67
11 ETRETINATE—for oral use 7, 62, 76
12 ETRETINATE—for topical use 62, 77
13 ENZALUTAMIDE 7, 67, 87
14 FARICIMAB 76
15 FINERENONE 67, 111
16 FINGOLIMOD 76
17 ISAVUCONAZOLE 53
18 ISOTRETINOIN—for oral use 7, 62, 76
19 ISOTRETINOIN—for topical use 62, 77
20 LEFLUNOMIDE 7, 62, 87
21 LENALIDOMIDE—for oral use 7, 62, 76
22 LENALIDOMIDE—for topical use 62, 77
23 LEVOCABASTINE 62
24 MACITENTAN 7, 62, 76
25 MISOPROSTOL 53
26 PALOVAROTENE 7, 62, 76, 111
27 PLITIDEPSIN 7, 62, 63, 76, 87
28 POMALIDOMIDE 7, 62, 76
29 PONESIMOD 76
30 RIOCIGUAT 7, 62, 76
31 RUFINAMIDE 62, 76, 77
32 SAFINAMIDE 62, 76, 77
33 SELINEXOR 62 and 77
34 SELUMETINIB. 76
35 SITAXENTAN 7, 62, 76
36 TERIFLUOMIDE 7, 62, 87
37 THALIDOMIDE—for oral use 7, 62, 76
38 THALIDOMIDE—for topical use 62, 77
39 TIRZEPATIDE 67
40 TRASTUZUMAB DERUXTECAN 62, 77
41 TRETINOIN—for oral use 7, 62, 76
42 TRETINOIN—for topical use 62, 77
Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist
Note: Appendix M is intentionally blank. It is reserved for future use.
CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2)
CYCLOSPORIN cross reference: CICLOSPORIN
CYCLOTHIAZIDE
CYCLOXYDIM
CYCRIMINE
Schedule 4 Appendix E, clause 3 Appendix F, clause 4
CYFLUFENAMID
CYFLUMETOFEN
CYFLUTHRIN
CYHALOFOP‑BUTYL
CYHALOTHRIN
CYHEXATIN
CYMARIN
CYMIAZOLE
CYNOGLOSSUM spp.
CYOMETRINIL
CYPERMETHRIN cross reference: ALPHA‑CYPERMETHRIN AND BETA‑CYPERMETHRIN, ZETA‑CYPERMETHRIN
CYPHENOTHRIN
CYPRINID HERPESVIRUS‑3
CYPROCONAZOLE
CYPRODINIL
CYPROHEPTADINE
CYPROTERONE
CYROMAZINE
CYSTEAMINE cross reference: MERCAPTAMINE
CYTARABINE
CYTHIOATE
D
2,4‑D
DABIGATRAN
DABRAFENIB MESILATE
DACARBAZINE
DACLATASVIR
DACLIZUMAB
DACTINOMYCIN
DALFOPRISTIN
DALTEPARIN
DAMINOZIDE
DANAPAROID
DANAZOL
DANTHRON
DANTROLENE
DAPAGLIFLOZIN
DAPOXETINE
DAPSONE
DAPTOMYCIN
DARATUMUMAB
DARBEPOETIN
DARIFENACIN
DAROLUTAMIDE
DARUNAVIR
DASABUVIR
DASATINIB
DATURA spp.
DATURA STRAMONIUM cross reference: STRAMONIUM
DATURA TATULA cross reference: STRAMONIUM
DAUNORUBICIN
DAZOMET
2,4‑DB
DEANOL cross reference: 2‑(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA
MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
MEDICAL DEVICES cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRA‑ARTICULAR FLUIDS, URINARY CATHETERS
MEDIGOXIN cross reference: METHYLDIGOXIN
MEDROXYPROGESTERONE
MEDRYSONE
MEFENAMIC ACID
MEFENOREX
MEFENPYR‑DIETHYL
MEFENTRIFLUCONAZOLE
MEFLOQUINE
MEFLUIDIDE
MEFRUSIDE
MEGASPHAERA ELSDENII strain 41125
MEGESTROL
MELAGATRAN
MELALEUCA OIL cross reference: TEA TREE OIL
MELANOTAN II cross reference: α–MELANOCYTE STIMULATING HORMONE
MELATONIN
MELENGESTROL
MELENGESTROL ACETATE
MELIA AZEDARACH
MELOXICAM
MELPHALAN
MEMANTINE
MENAZON
MENINGOCOCCAL VACCINE
MENINGOCOCCAL GROUP B VACCINE cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein
TIN ORGANIC COMPOUNDS cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN‑COMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS
TINIDAZOLE
TINZAPARIN
TIOCARBAZIL
TIOCONAZOLE
Schedule 4 Schedule 3 Schedule 2
TIOGUANINE cross reference: THIOGUANINE
TIOTROPIUM
TIPEPIDINE
TIPIRACIL
TIPRANAVIR
TIRBANIBULIN
TIRILAZAD
TIROFIBAN
TIRZEPATIDE
TISLELIZUMAB
TIXAGEVIMAB
TOBRAMYCIN
TOCAINIDE
TOCERANIB
TOCILIZUMAB
TOFACITINIB
TOLAZAMIDE
TOLAZOLINE
TOLBUTAMIDE
TOLCAPONE
TOLCLOFOS‑METHYL
TOLFENAMIC ACID
o‑TOLIDINE
Schedule 7 Appendix E, clause 3 Appendix J, clause 1